Short answer. There is no single best antimicrobial peptide design software, because the AMP toolchain splits into four jobs that different tools do: finding candidate sequences (classifiers such as amPEPpy, CAMPR4 and PyAMPA), generating or optimising new ones (generative models, mostly published academic code), looking up what has already been measured (DBAASP, CAMPR4, dbAMP, APD3), and predicting how a specific sequence will behave against specific organisms. A preclinical team usually needs one tool from the lookup group and one from the last group. The common and expensive mistake is buying two that both classify.
This is written for a peptide program of roughly five to fifty people with a real budget and a synthesis queue, not for an enterprise procurement committee. The comparison below is on the four things that actually decide the purchase at that size: whether the output names an organism, whether the price is published, what happens to your unpublished sequences, and how much engineering time the thing costs before it returns anything useful.
The four jobs, compared
Almost every tool in this space belongs to exactly one of these rows. Reading the row you are actually in saves more money than any individual product choice.
| Job | Examples | What it returns | Cost | Best for |
|---|---|---|---|---|
| Find candidates in a sequence set | amPEPpy, CAMPR4 predictors, PyAMPA, iAMPpred | A probability that each sequence is antimicrobial | Free, open source or academic web server | Mining a proteome or a metagenome before you have candidates |
| Generate or optimise sequences | Published generative models (VAE, GAN and transformer approaches), PyAMPA mutation modules | New sequences, or edits to an existing template | Free code, plus your own compute and engineering time | Teams with a computational biologist who can run and maintain research code |
| Look up what was already measured | DBAASP, CAMPR4, dbAMP, APD3, DRAMP | Curated records: sequence, target organism, measured MIC, haemolysis | Free | Everyone. These are the ground truth the rest of the stack sits on |
| Predict activity per organism | Antibacterial, plus a handful of species-specific research models | A predicted MIC band per strain, an S/I/R call, expected mechanism, confidence | Published, from $149 a month | Ranking a designed series against finite synthesis and plate capacity |
| Make the peptide | GenScript, Bachem and other synthesis vendors | Physical peptide, at a quoted purity | Quoted per sequence, per scale | The step everything above exists to spend wisely |
Classifiers are excellent, and they answer the wrong question once you have a series
The open classifiers are genuinely good software. amPEPpy is a portable command line random forest that runs on your own machine with no web submission, which matters if your sequences are unpublished. PyAMPA covers screening, validation and mutation in one bioinformatics package. CAMPR4 ships separate prediction algorithms for natural and synthetic peptides, which is a thoughtful distinction most tools skip.
They all return the same shape of answer: one number between 0 and 1, meaning roughly "this looks antimicrobial." That is exactly what you want when you are pulling candidates out of a genome. It is close to useless the moment a chemist walks in with forty analogs off a magainin template and asks which eight to synthesise. Every one of the forty will score high, because they are all obviously antimicrobial. The score does not separate them, does not name an organism, and does not tell you that twelve of them will lose an order of magnitude against Pseudomonas for reasons that live in the outer membrane rather than in the peptide.
That is the gap. It is also the most expensive gap in a peptide program, because the decision it blocks is a synthesis decision, and synthesis is where the money goes.
Generative design is real, and it is research code
The generative side has moved fast. Variational autoencoders, GANs and transformer architectures have all been applied to AMP sequence generation and optimisation, and the recent work coming out of the machine learning literature reports optimised peptides with genuine potency in animal infection models. This is not hype. It is also, almost without exception, published academic code rather than a product you can buy.
The practical consequence for a fifty person biotech is straightforward. You will be cloning a repository, resolving dependency conflicts against a two year old environment file, sourcing training data yourself, and maintaining the result with no support contract. If you have a computational biologist who wants that work, it is a reasonable investment and the ceiling is high. If your computational biologist is already the only person who can run the assay pipeline, this is how a quarter disappears.
The data sourcing is the part teams underestimate. Training or benchmarking anything sequence-based means assembling records out of several public databases that do not share a schema, and if you need that at scale rather than by hand, it is worth having a way to turn those database pages into clean structured records before you start modelling. Half the reported difficulty in AMP machine learning papers is really data plumbing.
The databases are the most undervalued tool in the stack
DBAASP is a manually curated database of peptides with measured antimicrobial activity against specific target organisms, covering thousands of ribosomal, non-ribosomal and synthetic peptides with activity reported against thousands of specific target microbes. CAMPR4 holds tens of thousands of AMP sequences along with structures, patents and family signatures. dbAMP and APD3 cover overlapping ground with different curation choices.
These are free, and they hold something none of the classifiers do: real measured MICs against named strains. If your series sits close to well characterised peptides, an afternoon in DBAASP will tell you more than any prediction. The limitation is that it does not scale and it does not rank. You cannot query forty analogs and get an ordered list, and the moment your sequences are novel enough to be interesting, the exact-match lookup stops returning anything.
What actually decides the purchase at a small company
| Criterion | Why it decides the purchase |
|---|---|
| Does the output name an organism | A sequence-level score cannot rank a series. If the tool never says A. baumannii, it cannot settle the argument in the project meeting. |
| Is the price published | Quote-based discovery software adds weeks before you know whether it is even in range. At a small company that delay is often the whole decision. |
| What happens to your sequences | Academic web servers and free wet screening schemes usually publish results eventually. That is fine for a university group and often fatal for a filing strategy. |
| Time to first useful answer | A hosted tool answers in seconds. Research code answers in weeks, after someone owns it. Both can be right, but only one is free. |
| Does it show its working | A number with no analogs behind it cannot be defended to a supervisor or a reviewer. Ask what the prediction rests on before you trust it with a synthesis slot. |
What is the best antimicrobial peptide prediction tool?
It depends which of the four jobs you are doing. For finding candidates in a large sequence set, amPEPpy and the CAMPR4 predictors are strong, free and well documented. For deciding which members of a designed series earn synthesis and plate time, you need a per-strain read-out rather than a classifier probability, which is what an antimicrobial peptide prediction tool with per-strain MIC output is for.
Can antimicrobial peptide activity be predicted from sequence?
Activity can be predicted as a band rather than an exact value. Net charge, hydrophobic moment, helicity and length carry most of the signal that drives membrane selectivity, and those features have been mapped against measured MICs for thousands of peptides. Reliability tracks how many characterised relatives your sequence has, which is why an honest tool reports confidence alongside every band.
Is generative AI worth it for antimicrobial peptide design?
It is worth it if you have the engineering capacity to run research code and a template you have already exhausted by hand. Generative models genuinely produce novel active sequences, with recent work reporting optimised peptides effective in animal infection models. For most preclinical teams the binding constraint is not idea generation. It is deciding which of the ideas already on the whiteboard deserve a synthesis slot.
How to sequence the toolchain without buying twice
A stack that works for a small program, in order:
- Start with the free databases. Search DBAASP and CAMPR4 for your template and its close relatives, and write down the measured MICs against the organisms you care about. This is your baseline and it costs nothing but an afternoon.
- Use a classifier only if you are mining sequences rather than designing them. If your peptides came off a known template, skip this step entirely. You already know they are antimicrobial.
- Predict per strain across the whole designed series, and rank. This is the step that converts forty analogs into eight with a written reason for the other thirty-two, and it is the step most stacks are missing.
- Synthesise and assay the top few, then feed the measured numbers back. The measured minimum inhibitory concentration is the ground truth and always was. Prediction only decides what gets measured.
- Reach for generative design once the obvious edits to the template are exhausted and you have an owner for the code.
The honest summary
If you are mining sequences, the free classifiers are the right answer and you should not pay for anything. If you are optimising a known template with a computational biologist to spare, the generative literature is worth the engineering. If you have a designed series, a synthesis queue and a decision due, the missing piece is almost always per-strain activity prediction, because that is the only output that ranks compounds against the organisms your program is actually about.
Peptides are unusually punishing here. A sequence can be excellent against MRSA and thirty-two fold weaker against Gram-negative bacteria, and no sequence-level score will ever tell you that, because the difference is not in the peptide. Background on why that gap exists, and on the haemolysis and protease liabilities that kill most peptide programs before potency does, is in the reference note on antimicrobial peptides. If you also screen small molecules alongside your peptide work, the same account covers both through the MIC prediction software read-out.